Introduction: Penicillins and cephalosporins are the most frequent causes of hypersensitivity reactions (HRs) to drugs in children. Among cephalosporins for intravenous use, ceftriaxone (CT) is the most frequently prescribed in Italy. The aims of this study were to evaluate the diagnostic methods for CT hypersensitivity in a population of children with suspected HRs to this drug and their tolerance toward amoxi-cillin/clavulanic acid (AMX/CLV). Materials and Methods: From 2012 to 2018, 90 children were investigated for suspected HRs to CT according to the European Academy of Allergy Asthma and Clinical Immunology (EAACI) guidelines. Results: Ninety children had a history of reaction to CT. The majority (79/90; 77.8%) had a history of immediate reactions (IRs). CT hypersensitivity was confirmed in 26/90 patients (28.9%). In case of IRs, skin tests can be useful (24% of positive CT intradermal tests – IDTs) particularly in cases of anaphylaxis (81.8% of positive CT IDTs). Only 5 out of 28 drug provocation tests were positive. Serum-specific IgE (sIgE) determination for CT correlated with positivity upon skin/drug provocation tests (high specificity 95.6%) but had a low sensitivity; sIgE for AMX had a very low positive predictive value (14.3%), advocating against its use. In case of non-IRs, only 7/11 patients reached a confident diagnosis, but the low number of children does not enable proper conclusions. Only 2 children showed cross- and/or co-allergy (2.2%) between CT and AMX/CLV. Conclusion: IDTs seem to be useful for diagnosing CT IRs. Hypersensitivity to CT is confirmed in 28.9% of children, although a large fraction of parents refused an intravenous rechallenge (45.6%). It remains unknown whether this is due to the fact this was intravenous rather than a rechallenge with the culprit, but it reflects a clinical reality. Otherwise, cross- and/or co-allergy between CT and AMX/CLV is a rare event.

1.
Romano
A
,
Torres
MJ
,
Castells
M
,
Sanz
ML
,
Blanca
M
.
Diagnosis and management of drug hypersensitivity reactions
.
J Allergy Clin Immunol
.
2011
Mar
;
127
(
3
Suppl
):
S67
73
.
[PubMed]
0091-6749
2.
Romano
A.
Cross-reactivity and tolerability of cephalosporins in patients with IgE-mediated Hypersensitivity to penicillins. J Allergy Clin Immunol Pract [Epub ahead of print]
3.
Zagursky
RJ
,
Pichichero
ME
.
Cross-reactivity in β-Lactam Allergy
.
J Allergy Clin Immunol Pract
.
2018
Jan - Feb
;
6
(
1
):
72
81.e1
.
[PubMed]
2213-2198
4.
Ponvert
C
,
Perrin
Y
,
Bados-Albiero
A
,
Le Bourgeois
M
,
Karila
C
,
Delacourt
C
, et al.
Allergy to betalactam antibiotics in children: results of a 20-year study based on clinical history, skin and challenge tests
.
Pediatr Allergy Immunol
.
2011
Jun
;
22
(
4
):
411
8
.
[PubMed]
0905-6157
5.
Piovani
D
,
Clavenna
A
,
Cartabia
M
,
Bonati
M
;
Antibiotic Collaborative Group
.
The regional profile of antibiotic prescriptions in Italian outpatient children
.
Eur J Clin Pharmacol
.
2012
Jun
;
68
(
6
):
997
1005
.
[PubMed]
0031-6970
6.
Italian Medicine Agency
.
Ceftriaxone e reazioni avverse nei bambini.
Bollettino d’informazione sui farmaci. XV:N.4;
2008
.
7.
Manfredi
M
,
Severino
M
,
Testi
S
,
Macchia
D
,
Ermini
G
,
Pichler
WJ
, et al.
Detection of specific IgE to quinolones
.
J Allergy Clin Immunol
.
2004
Jan
;
113
(
1
):
155
60
.
[PubMed]
0091-6749
8.
Brockow
K
,
Garvey
LH
,
Aberer
W
,
Atanaskovic-Markovic
M
,
Barbaud
A
,
Bilo
MB
, et al.;
ENDA/EAACI Drug Allergy Interest Group
.
Skin test concentrations for systemically administered drugs— an ENDA/EAACI Drug Allergy Interest Group position paper
.
Allergy
.
2013
Jun
;
68
(
6
):
702
12
.
[PubMed]
0105-4538
9.
Romano
A
,
Gaeta
F
,
Valluzzi
RL
,
Maggioletti
M
,
Zaffiro
A
,
Caruso
C
, et al.
IgE-mediated hypersensitivity to cephalosporins: cross-reactivity and tolerability of alternative cephalosporins
.
J Allergy Clin Immunol
.
2015
Sep
;
136
(
3
):
685
691.e3
.
[PubMed]
0091-6749
10.
Warrington
R
,
Silviu-Dan
F
.
Drug allergy
.
Allergy Asthma Clin Immunol
.
2011
Nov
;
7
Suppl 1
:
S10
.
[PubMed]
1710-1484
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.